GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Apr 25, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-repurchase
TL;DR
GSK bought back some of its own stock on 4/24/25 via Citigroup.
AI Summary
GSK plc announced on April 24, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine share repurchase announcement with no immediate negative financial implications.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- 24 April 2025 (date) — Date of purchase
FAQ
What was the specific number of GSK ordinary shares purchased on April 24, 2025?
The filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity.
What was the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the share repurchase.
Who acted as GSK's corporate stockbroker for this transaction?
Citigroup Global Markets Limited acted as GSK's corporate stockbroker.
What is the nominal value of GSK's ordinary shares?
The ordinary shares are described as having a nominal value of 31 1/4 pence each.
Is this a new share issuance or a repurchase?
This filing is a 'Transaction in own shares,' indicating a repurchase of shares by GSK.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 25, 2025 regarding GSK plc (GLAXF).